CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Siltuximab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04191421
NCT04191421Phase 2Completed
CompareCT.gov

A Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer

Emory University·interventional·Posted Dec 9, 2019·Updated Aug 22, 2025

In Brief

A Phase 2 clinical trial evaluating Siltuximab and Spartalizumab for Metastatic Pancreatic Adenocarcinoma and Stage IV Pancreatic Cancer AJCC v8. Completed, enrolled 35 participants across 3 sites.

Detailed Summary

This phase Ib/II trial studies the best dose and side effects of siltuximab and how well it works in combination with spartalizumab in treating patients with pancreatic cancer that has spread to other places in the body. Monoclonal antibodies, such as siltuximab and spartalizumab, interfere with the ability of tumors cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
CountriesUnited States
CollaboratorsNovartis, EUSA Pharma, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 9, 2019
Enrollment StartJan 17, 2020
Primary CompletionApr 5, 2023
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.6 years ago

Interventions

Siltuximabbiological

Given IV

Spartalizumabbiological

Given IV